GSK profit jumps on strong specialty medicine sales

London, United Kingdom: British pharmaceutical group GSK reported Wednesday a sharp rise in net profit last year, boosted by strong HIV, respiratory a...

London, United Kingdom: British pharmaceutical group GSK reported Wednesday a sharp rise in net profit last year, boosted by strong HIV, respiratory and cancer drug sales as it recovered from costly US lawsuits over its Zantac heartburn drug.

Profit after tax climbed to £5.7 billion ($7.8 billion) compared with profit of £2.6 billion in 2024, GSK said in a statement.

Revenue rose four percent to £32.7 billion.

"GSK delivered another strong performance in 2025, driven mainly by Specialty Medicines," said chief executive Luke Miels, who took over from Emma Walmsley at the start of the year.

"We expect this positive momentum to continue in 2026," he added.